Genetic proxies for PCSK9 inhibition associate with lipoprotein(a): Effects on coronary artery disease and ischemic stroke.

Publication

Genetic proxies for PCSK9 inhibition associate with lipoprotein(a): Effects on coronary artery disease and ischemic stroke.

Journal Paper/Review - Sep 26, 2022

De Marchis Gian Marco, Dittrich Tolga, Malik Rainer, Zietz Annaelle, Kriemler Lilian, Ference Brian A, Dichgans Martin, Georgakis Marios K

Citation

De Marchis G, Dittrich T, Malik R, Zietz A, Kriemler L, Ference B, Dichgans M, Georgakis M. Genetic proxies for PCSK9 inhibition associate with lipoprotein(a): Effects on coronary artery disease and ischemic stroke. Atherosclerosis 2022; 361:41-46.

Type

Journal Paper/Review (English)

Journal

Atherosclerosis 2022; 361

Publication Date

Sep 26, 2022

Issn Electronic

1879-1484

Pages

41-46

Brief description/objective

Post hoc analyses of clinical trials show that PCSK9 inhibitors might lower lipoprotein(a), but whether this effect contributes to reductions in cardiovascular risk remains unknown. We aimed to assess whether genetically proxied PCSK9 inhibition influences lipoprotein(a) (Lp(a)), and whether any such effect could mediate its effects on coronary artery disease (CAD) and ischemic stroke (IS).